Skip to content Skip to footer
Subscribe Now
Top 20 immunology companies of 2025
TOP 20

Top 20 Immunology Companies of 2025

Shots: Immunology continues to be a key focus area, with biopharmaceutical companies rigorously advancing innovative therapies including drugs, vaccines, and antibodies to address evolving patient needs and improve disease outcomes In 2024, the global immunology market size was valued at $109.4B and expected to reach $254.23B by 2032, with a CAGR of 11.8% from 2024…
July 24, 2025

Read more

Sandoz
NEWS

Sandoz Introduces Tyruko (Biosimilar, Tysabri) for Multiple Sclerosis in Germany 

Shots : Sandoz has introduced Tyruko (natalizumab), biosimilar of Tysabri for the treatment of r/r multiple sclerosis (RRMS), in Germany which will be available from Feb 1  Polpharma Biologics is responsible for the development, manufacturing and supply of Tyruko while Sandoz holds its commercialization rights in all markets as per a global commercialization agreement signed…
January 31, 2024

Read more

PharmShots Interview In Conversation with Biogen’s Vice President, Monica Mann, Where she Shares Insights on The Publication of Data from the NOVA Study to Treat Multiple Sclerosis
VIEWPOINTS

PharmShots Interview: In Conversation with Biogen’s Vice President, Monica Mann, Where she Shares Insights on The Publication of Data from the NOVA Study to Treat Multiple Sclerosis

Shots:Monica spoke about the data from the NOVA P-IIIb study evaluating the efficacy of its lead candidate in Multiple Sclerosis(MS)Monica also talked about the clinical trial results and formulation of the advanced product in MSThe interview gives a view of Biogen’s developing molecules in the pipeline for MSSmriti: Can you share with…
July 5, 2022

Read more

PharmaShots Interview Biogen’s Monica Mann Shares Insights on the New Real-World Data on Tysabri & Vumerity for the Treatment of Multiple Sclerosis
VIEWPOINTS

PharmaShots Interview: Biogen’s Monica Mann Shares Insights on the New Real-World Data on Tysabri & Vumerity for the Treatment of Multiple Sclerosis

In an interview with PharmaShots, Monica Mann, Vice President, Medical Affairs for Global MS and Pipeline at Biogen shared her views on the data of Tysabri, Vumerity & highlights of new digital health research to predict multiple sclerosis disease progressionShots:Monica spoke about detailed results of the new real-world & clinical data on the long-term use of Tysabri & real-world analyses…
May 17, 2022

Read more